Coherus Oncology, Inc. (CHRS )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol CHRS
- Company Coherus Oncology, Inc.
- Price $0.75
- Changes Percentage -9.72
- Change -0.0807
- Day Low $0.75
- Day High $0.84
- Year High $2.62
- Year Low $1.09
- Market Cap $180,766,122
- Price Avg 50 EMA (D) $1.36
- Price Avg 200 EMA (D) $1.58
- Exchange NASDAQ
- Volume 1,561,562
- Average Volume 1,129,522
- Open $0.84
- Previous Close $0.83
- EPS -1.11
- PE -1.05
- Earnings Announcement 2026-11-05 05:00:00
- Shares Outstanding $154,500,959
Company brief: COHERUS ONCOLOGY, INC. (CHRS )
- Healthcare
- Biotechnology
- Mr. Dennis M. Lanfear
- https://www.coherus.com
- US
- N/A
- 11-06-2014
- US19249H1032
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.